CN112263679B - Targeted oxygen-carrying nano sound-sensitive agent and preparation method thereof - Google Patents
Targeted oxygen-carrying nano sound-sensitive agent and preparation method thereof Download PDFInfo
- Publication number
- CN112263679B CN112263679B CN202011157001.9A CN202011157001A CN112263679B CN 112263679 B CN112263679 B CN 112263679B CN 202011157001 A CN202011157001 A CN 202011157001A CN 112263679 B CN112263679 B CN 112263679B
- Authority
- CN
- China
- Prior art keywords
- oxygen
- manganese
- porphyrin
- sound
- carrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- XJJWWOUJWDTXJC-UHFFFAOYSA-N [Mn].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical compound [Mn].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 XJJWWOUJWDTXJC-UHFFFAOYSA-N 0.000 claims description 51
- 239000003795 chemical substances by application Substances 0.000 claims description 45
- 239000002245 particle Substances 0.000 claims description 44
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 34
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 34
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 108010054147 Hemoglobins Proteins 0.000 claims description 14
- 102000001554 Hemoglobins Human genes 0.000 claims description 14
- 229910052751 metal Inorganic materials 0.000 claims description 13
- 239000002184 metal Substances 0.000 claims description 13
- 108010064719 Oxyhemoglobins Proteins 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000011259 mixed solution Substances 0.000 claims description 10
- HJCNSOVRAZFJLK-UHFFFAOYSA-N C1=CC(C(=O)O)=CC=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 HJCNSOVRAZFJLK-UHFFFAOYSA-N 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 238000009210 therapy by ultrasound Methods 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 8
- 238000004440 column chromatography Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 229910001437 manganese ion Inorganic materials 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 230000000536 complexating effect Effects 0.000 claims description 6
- 150000002696 manganese Chemical class 0.000 claims description 6
- 229940071125 manganese acetate Drugs 0.000 claims description 5
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 claims description 5
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 4
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 4
- 239000011261 inert gas Substances 0.000 claims description 4
- 235000002867 manganese chloride Nutrition 0.000 claims description 4
- 239000011565 manganese chloride Substances 0.000 claims description 4
- 229940099607 manganese chloride Drugs 0.000 claims description 4
- 229940099596 manganese sulfate Drugs 0.000 claims description 4
- 235000007079 manganese sulphate Nutrition 0.000 claims description 4
- 239000011702 manganese sulphate Substances 0.000 claims description 4
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical class [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 48
- 230000008685 targeting Effects 0.000 abstract description 22
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 16
- 239000001301 oxygen Substances 0.000 abstract description 16
- 229910052760 oxygen Inorganic materials 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 11
- 206010021143 Hypoxia Diseases 0.000 abstract description 4
- 230000007954 hypoxia Effects 0.000 abstract description 4
- 150000004032 porphyrins Chemical class 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- 239000002105 nanoparticle Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 150000002678 macrocyclic compounds Chemical class 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 230000005526 G1 to G0 transition Effects 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 4
- 206010034972 Photosensitivity reaction Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000012295 chemical reaction liquid Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 208000007578 phototoxic dermatitis Diseases 0.000 description 4
- 231100000018 phototoxicity Toxicity 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 238000009214 sonodynamic therapy Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 101000773038 Human herpesvirus 7 (strain RK) U21 glycoprotein Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000007626 photothermal therapy Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 description 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- FPVGTPBMTFTMRT-UHFFFAOYSA-L disodium;2-amino-5-[(4-sulfonatophenyl)diazenyl]benzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019233 fast yellow AB Nutrition 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a targeted oxygen-carrying nano sound sensitizer and a preparation method thereof. The preparation method is simple in preparation process, and the prepared targeting oxygen-carrying nano sound sensitizer is stable in property, high in bioavailability and good in targeting property, and can be used for efficiently and targeted delivery of exogenous oxygen molecules and MnPP into tumors, so that the tumor hypoxia microenvironment is improved, and the sound power curative effect is improved.
Description
Technical Field
The invention relates to the field of nano medicine, in particular to a targeted oxygen-carrying nano sound sensitizer and a preparation method thereof.
Background
In the prior art, optical treatment of tumors has become a research hotspot for cancer treatment due to the non-invasive and space-time controllable advantageous features. Tumour optical treatments mainly include photodynamic therapy (PDT) and photothermal therapy (PTT). However, near infrared light has a limited tissue penetration depth, and the therapeutic effect of deep tumors is poor. In contrast, sonodynamic therapy (SDT) attracts a great deal of attention, and uses the stronger penetrating power of ultrasound to treat tumors by generating Reactive Oxygen Species (ROS) or cavitation effects from sonosensitizers accumulated in deep tumors. Currently, sonodynamic therapy has been used clinically, combining endocrine and immunotherapy to successfully cure 3 cases of advanced breast cancer patients. Common sonosensitizer molecules include: porphyrin, porphyrin derivative, anticancer medicine DOX, acid yellow, methylene blue, polyhydroxy fullerene and other organic molecules. However, these traditional organic sonosensitizer molecules have the problems of low bioavailability, oxygen dependence, lack of tumor targeting and the like, which results in low sonodynamic therapeutic efficiency and seriously hinders the clinical popularization of the method.
In recent years, the rapid development of global nanotechnology brings a brand new revolution to cancer treatment. The novel drug carrier of the nano material can realize specific targeting positioning, and efficiently enrich the drugs to tumor focus; and simultaneously, the size, morphology, surface charge, ligand modification and other physicochemical properties of the nano particles are regulated, so that a high-density interstitial matrix barrier formed by collagen, mucopolysaccharide, proteoglycan and the like in the tumor is broken through, and the loaded medicine is delivered into the tumor, thereby enhancing the anti-tumor curative effect. Aiming at the bottleneck problems of low bioavailability, poor targeting property, oxygen dependence and the like of the traditional sound sensitive agent, the nanotechnology provides a new strategy and a new direction, and brings a new opportunity for the clinical popularization of a novel nano sound dynamic pharmaceutical preparation. Development of novel nano-sonosensitizers with high bioavailability, good targeting property and capability of improving tumor hypoxia microenvironment has become an important research direction in the field of current acoustic power treatment.
However, the existing nano sound sensitive agent has complex preparation process, cannot prepare large volume, has unstable property, is easy to precipitate and flocculate, still has some problems such as sound sensitive agent safety and the like, and prevents the clinical popularization of sound power treatment.
Hybrid systems of human serum albumin and oxyhemoglobin are reported in the prior art, but high-efficiency and low-toxicity sound sensitizer is not added, and high-efficiency treatment of deep tumors cannot be realized. The three major factors of acoustic power are: ultrasound, oxygen and sonophores. Ultrasound can be up to 10cm deep, so that when nanoparticles penetrate deep into the tumor, other means such as light, even two-zone, cannot achieve such deep penetration. Under the condition of deep ultrasonic penetration, the sound-sensitive agent can effectively play a role, and realize the high-efficiency treatment of deep tumors. Nanoparticles of human serum albumin coated manganese porphyrin sonosensitizers have also been reported in the prior art, but are not capable of carrying oxygen efficiently, and therefore do not play a role in efficient sonodynamic therapy.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the targeted oxygen-carrying nano sound sensitizer which has the advantages of simple preparation process, stable property, high safety, high bioavailability and good targeting property, and can realize high-efficiency sound power treatment. The disulfide bond breaking-reconstructing technology is adopted, the Human Serum Albumin (HSA) and the oxyhemoglobin (Hb) are hybridized by a one-step ultrasonic method, the hydrophobic sound-sensitive agent manganese porphyrin (MnPP) is wrapped, the targeted oxygen-carrying nanometer sound-sensitive agent is prepared, and exogenous oxygen molecules and MnPP are efficiently and targeted and delivered into the tumor, so that the tumor hypoxia microenvironment is improved, and the sound power curative effect is improved.
The invention provides a targeted oxygen-carrying nano sound-sensitive agent, which is characterized in that the exterior is a hybrid protein body, the interior is wrapped with sound-sensitive agent manganese porphyrin, and the hybrid protein body consists of human serum albumin and oxygen-carrying hemoglobin.
The targeting oxygen-carrying nano sound-sensitive agent has a spherical structure, and forms stronger intermolecular force with the manganese porphyrin sound-sensitive agent with a macrocyclic conjugated structure, so that the manganese porphyrin sound-sensitive agent is efficiently wrapped in the hybrid protein body, the water solubility of the manganese porphyrin sound-sensitive agent is improved, and the bioavailability of the manganese porphyrin sound-sensitive agent is improved.
The oxygen-carrying hemoglobin can carry oxygen with high efficiency and can enhance the effect of sound power treatment.
The human serum albumin has a tumor specific targeting function, and can be used for efficiently targeting tumors through gp60 glycoprotein receptor-mediated tumor endothelial cell penetration effect and tumor cell secretion protein SPARC-mediated enhanced uptake mechanism.
Further, the manganese porphyrin is formed by complexing metal manganese ions with a macrocyclic compound with a porphyrin structure. After complexing the metal manganese ion with the macrocyclic compound with the porphyrin structure, the fluorescent resonance energy transfer effect is generated, so that the fluorescence quenching of the porphyrin sound sensitizer is realized, and the phototoxicity of the porphyrin sound sensitizer is reduced.
The oxygen-carrying nano sound sensitizer can target and deliver exogenous oxygen molecules and manganese porphyrin into tumors.
The invention also provides a preparation method of the targeted oxygen-carrying nano sound sensitizer, which comprises the following steps:
(1) Preparation of manganese porphyrin: mixing a macrocyclic compound with a porphyrin structure with a metal manganese salt, filtering the precipitate, and drying;
(2) And (3) preparing the targeted oxygen-carrying nano sound sensitizer by using human serum albumin, oxygen-carrying hemoglobin and manganese porphyrin obtained in the step (1).
Further, the macrocyclic compound of the porphyrin structure and the metal manganese salt in the step (1) are in an equimolar ratio.
Further, the macrocyclic compound of the porphyrin structure is 5,10,15, 20-tetra (4-carboxyphenyl) porphyrin.
Further, the metal manganese salt in the step (1) includes at least one of manganese chloride, manganese sulfate or manganese acetate.
Further, the step (1) includes a step of performing reaction protection by using an inert gas, wherein the inert gas is at least one of nitrogen and argon.
Further, the separation step in the step (1) uses column chromatography with silica gel as a stationary phase and methylene chloride and methanol as mobile phases.
Further, the mass ratio of the human serum albumin to the oxyhemoglobin in the step (2) is 1-5:1. this ratio affects the particle size of the targeted oxygen-carrying nanoacoustic sensitizer.
Further, the step (2) includes a step of sonicating a mixed solution of the human serum albumin, the oxyhemoglobin, and the manganese porphyrin using a cytobreaker.
Further, the ultrasonic treatment time is 5-20min. The ultrasonic time can influence the particle size of the oxygen-carrying nano sound-sensitive agent.
Further, the pH value of the mixed solution is 7-8. The pH value directly influences the particle size of the oxygen-carrying nano sound-sensitive agent, and the particle size directly determines the enrichment amount of the oxygen-carrying nano sound-sensitive agent at the tumor part.
The invention also provides application of the oxygen-carrying nano sound sensitizer in preparing antitumor drugs.
In conclusion, compared with the prior art, the invention achieves the following technical effects:
1. the preparation method can prepare a large volume of targeted oxygen-carrying nano sound sensitizer, can prepare more than a few liters, and the volume of the nano particles obtained by the preparation method in the prior art is hundreds of milliliters at most, so the preparation method provides a foundation for the amplified production and clinical research of the nano particles.
2. The targeted oxygen-carrying nano sound sensitizer prepared by the invention can be stably stored, and does not have sedimentation or flocculation phenomenon in one year.
3. The preparation method is simple and easy to implement, and the targeted oxygen-carrying nano sound-sensitive agent with uniform particle size can be prepared by adding the raw materials in two steps under stirring, does not need any high-temperature and complex equipment or harsh reaction conditions, and is convenient to operate and popularize.
4. After complexing the metal manganese ion and the macrocyclic compound with the porphyrin structure, the phototoxicity of the porphyrin sound-sensitive agent is reduced, and the safety is improved.
5. The invention improves the water solubility of the manganese porphyrin sound-sensitive agent, thereby improving the bioavailability thereof.
6. The human serum albumin has a tumor specific targeting function, so that the oxygen-carrying nano sound sensitizer has good targeting property.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings that are needed in the embodiments will be briefly described below, it being understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and other related drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a UV-Vis absorption spectrum of a manganese porphyrin sound-sensitive molecule in example 4.
FIG. 2 is a transmission electron microscope image of the targeted oxygen-carrying nanosonic sensitizer of example 4.
FIG. 3 is a graph showing the results of the targeting oxygen-carrying nanoscopic agents of the present invention in example 5 that effectively carry oxygen molecules into tumors.
Fig. 4 is a graph showing the results of the effective inhibition of tumor growth by the targeted oxygen-carrying nanoacoustic sensitizer of the present invention in example 6.
Detailed Description
In order that those skilled in the art will better understand the present invention, a technical solution in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in which it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, shall fall within the scope of the invention.
The targeted oxygen-carrying nano sound sensitizer can realize safe and efficient targeting of the inside of a tumor, thereby improving the anoxic microenvironment of the tumor and improving the sound power curative effect, and the principle is as follows:
1. after complexing metal manganese ions with a macrocyclic compound with a porphyrin structure, generating a fluorescence resonance energy transfer effect, thereby quenching the fluorescence of the porphyrin sound sensitizer and reducing the phototoxicity of the porphyrin sound sensitizer;
2. after porphyrin molecule metal coordination, the metalloporphyrin triplet state (3 MTTP) generated by ultrasonic action is effectively combined with oxygen molecules, so that the active oxygen yield of metalloporphyrin is remarkably improved, and the metalloporphyrin is an ideal sound sensitizer molecule;
3. the targeted oxygen-carrying nano sound-sensitive agent has a spherical structure, and forms stronger intermolecular force with the manganese porphyrin sound-sensitive agent with a macrocyclic conjugated structure, so that the manganese porphyrin sound-sensitive agent is efficiently wrapped in the hybrid protein body, the water solubility of the manganese porphyrin sound-sensitive agent is improved, and the bioavailability of the manganese porphyrin sound-sensitive agent is improved;
4. the invention adopts the components in the human body: the human serum albumin and the oxyhemoglobin are used as heterozygous carriers, so that the safety is high;
5. human serum albumin has tumor specific targeting function: the tumor is efficiently targeted by a gp60 glycoprotein receptor-mediated tumor endothelial cell penetrating effect and a tumor cell secretion protein SPARC-mediated enhanced uptake mechanism;
6. manganese ions released by degradation of the targeted oxygen-carrying nanosonic sensitizer can be used for magnetic resonance imaging.
The preparation method of the targeted oxygen-carrying nano sound-sensitive agent is characterized in that the targeted oxygen-carrying nano sound-sensitive agent is prepared by adopting a one-step ultrasonic method, and hydrophobic manganese porphyrin is wrapped in a hybrid protein body along with volatilization of a chloroform solvent to form the spherical targeted oxygen-carrying nano sound-sensitive agent. The method comprises the following specific steps:
(1) Preparation of manganese porphyrin
(1) Mixing a macrocyclic compound with porphyrin structure (such as 5,10,15, 20-tetra (4-carboxyphenyl) porphyrin, PP) with metal manganese salt (at least one of manganese chloride, manganese sulfate or manganese acetate), stirring under the protection of inert gas, heating and refluxing, stopping the reaction, and cooling to room temperature;
(2) the precipitate was filtered, washed with deionized water and dried in vacuo. Separating by column chromatography, rotary evaporating at low temperature, drying, and collecting sample to obtain manganese porphyrin (MnPP).
(2) Preparation of targeted oxygen-carrying nano sound sensitizer
(1) Weighing manganese porphyrin, and dissolving the manganese porphyrin in chloroform;
(2) weighing oxyhemoglobin powder, dissolving in ultrapure water, and placing in a shaking table for reaction;
(3) the human serum albumin and the oxyhemoglobin are mixed according to the mass ratio of 1-5:1, mixing, and transferring the manganese porphyrin solution in the step (1) to the bottom of the mixed solution;
(4) and (3) placing the mixed solution in an ice-water bath, performing ultrasonic treatment by using a cell pulverizer to form a suspension, adjusting the pH value to 7-8, and then placing the suspension in an ultrasonic cleaner for ultrasonic treatment until the suspension becomes clear, thus obtaining the targeted oxygen-carrying nano sound sensitizer.
Example 1 preparation method of Targeted oxygen-carrying nanosonic agent
The method specifically comprises the following steps:
(1) Preparation of manganese porphyrin
(1) Mixing 5,10,15, 20-tetra (4-carboxyphenyl) porphyrin (PP) purchased from the technical Co., ltd. Of carbofuran and manganese chloride in anhydrous DMF solution, stirring, heating and refluxing for 2 hours under the protection of nitrogen, monitoring the reaction progress by a UV-Vis absorption spectrometer, and stopping the reaction after the reaction liquid is changed from black red to grass green and the Q band peak is changed from 4 to 2 with a certain degree of red shift, and cooling to room temperature;
(2) the precipitate was filtered, washed with deionized water and dried in vacuo. Separating by column chromatography, and taking silica gel as stationary phase, wherein the volume ratio is 3:1 as mobile phase. And (5) rotary evaporation at low temperature, drying and collecting a sample to obtain manganese porphyrin (MnPP).
(2) Preparation of targeted oxygen-carrying nano sound sensitizer
(1) Weighing 1mg of manganese porphyrin, and dissolving in 100 mu L of chloroform;
(2) 5mg of Hb powder was weighed, dissolved in 1mL of ultrapure water, and placed in a shaker to react for 0.5h under the following reaction conditions: 37 ℃,100rpm;
(3) HSA and Hb are mixed according to the mass ratio of 1:1, uniformly mixing, and transferring 100 mu L of the manganese porphyrin solution in the step (1) to the bottom of the mixed solution;
(4) placing the above mixture in ice water bath, performing ultrasonic treatment with cell pulverizer for 5min to obtain suspension, and treating with Na 2 CO 3 And regulating the pH value of the solution to 7, and then placing the solution in an ultrasonic cleaner for ultrasonic until the suspension becomes clear, thus obtaining the targeted oxygen-carrying nano sound sensitizer.
The zeta potential of the targeted oxygen-carrying nano sound sensitizer is larger than-30 mV, the particle size range is 50-200nm, and the results of potential and particle size can prove that the targeted oxygen-carrying nano sound sensitizer is successfully prepared. However, the particle size range of the targeted oxygen-carrying nano sound sensitizer is slightly larger, and the uniformity of the particle size is not high. This is related to the ratio of human serum albumin to oxyhemoglobin, the pH of the solution, the time of sonication.
Example 2 preparation method of Targeted oxygen-carrying nanosonic agent
In this example, the ratio of human serum albumin to oxygen-carrying hemoglobin, the pH value of the system, and the time of ultrasound are different from those of example 1, the pH value directly affects the particle size of the oxygen-carrying nanoacoustic sensitizer, and the particle size directly determines the enrichment amount of the oxygen-carrying nanoacoustic sensitizer at the tumor site. The ultrasonic time directly affects the particle size of the oxygen-carrying nano-sonosensitizer, and the ratio of human serum albumin to oxygen-carrying hemoglobin can also affect the particle size.
The method specifically comprises the following steps:
(1) Preparation of manganese porphyrin
(1) Mixing 5,10,15, 20-tetra (4-carboxyphenyl) porphyrin (PP) and manganese acetate in an equal molar ratio into anhydrous DMF solution, stirring under the protection of argon, heating and refluxing for 6 hours, monitoring the reaction progress by a UV-Vis absorption spectrometer, stopping the reaction after the reaction liquid changes from black red to grass green and the Q band peak changes from 4 to 2 with a certain degree of red shift, and cooling to room temperature;
(2) the precipitate was filtered, washed with deionized water and dried in vacuo. Separating by column chromatography, and taking silica gel as stationary phase, wherein the volume ratio is 3:1 as mobile phase. And (5) rotary evaporation at low temperature, drying and collecting a sample to obtain manganese porphyrin (MnPP).
(2) Preparation of targeted oxygen-carrying nano sound sensitizer
(1) Weighing 5mg of manganese porphyrin, and dissolving in 500 mu L of chloroform;
(2) 10mg of Hb powder was weighed, dissolved in 5mL of ultrapure water, and placed in a shaker to react for 2 hours under the following conditions: 37 ℃,200rpm;
(3) HSA and Hb are mixed according to the mass ratio of 5:1, uniformly mixing, and transferring 500 mu L of manganese porphyrin solution in the step (1) to the bottom of the mixed solution;
(4) placing the above mixture in ice water bath, performing ultrasonic treatment with cell pulverizer for 20min to obtain suspension, and treating with Na 2 CO 3 And regulating the pH value of the solution to 8, and then placing the solution in an ultrasonic cleaner for ultrasonic until the suspension becomes clear, thus obtaining the targeted oxygen-carrying nano sound sensitizer.
The zeta potential of the targeted oxygen-carrying nano sound sensitizer is larger than-30 mV, and the particle size range is 80-200nm. The results of the potential and the particle size can indicate that the targeted oxygen-carrying nano sound sensitizer is successfully prepared. The particle size range of the targeted oxygen-carrying nano-sonosensitizer is slightly reduced compared with that of the example 1, but the particle size range is still large, and the particle size uniformity degree is not high, which is related to the ratio of the human serum albumin and the oxygen-carrying hemoglobin, the pH value of the solution and the ultrasonic time. The targeted oxygen-carrying nano sound sensitizer with more uniform particle size can be prepared by continuously optimizing the conditions.
Example 3 preparation method of Targeted oxygen-carrying nanosonic agent
In this example, the ratio of human serum albumin to oxygen-carrying hemoglobin, the pH value of the system, and the time of ultrasound are different from those of example 1, the pH value directly affects the particle size of the oxygen-carrying nanoacoustic sensitizer, and the particle size directly determines the enrichment amount of the oxygen-carrying nanoacoustic sensitizer at the tumor site. The ultrasonic time directly affects the particle size of the oxygen-carrying nano-sonosensitizer, and the ratio of human serum albumin to oxygen-carrying hemoglobin can also affect the particle size.
The method specifically comprises the following steps:
(1) Preparation of manganese porphyrin
(1) Mixing 5,10,15, 20-tetra (4-carboxyphenyl) porphyrin (PP) and manganese acetate in an equal molar ratio into anhydrous DMF solution, stirring under the protection of argon, heating and refluxing for 6 hours, monitoring the reaction progress by a UV-Vis absorption spectrometer, stopping the reaction after the reaction liquid changes from black red to grass green and the Q band peak changes from 4 to 2 with a certain degree of red shift, and cooling to room temperature;
(2) the precipitate was filtered, washed with deionized water and dried in vacuo. Separating by column chromatography, and taking silica gel as stationary phase, wherein the volume ratio is 3:1 as mobile phase. And (5) rotary evaporation at low temperature, drying and collecting a sample to obtain manganese porphyrin (MnPP).
(2) Preparation of targeted oxygen-carrying nano sound sensitizer
(1) Weighing 1mg of manganese porphyrin, and dissolving in 200 mu L of chloroform;
(2) 5mg of Hb powder was weighed, dissolved in 1mL of ultrapure water, and placed in a shaker to react for 0.5h under the following reaction conditions: 37 ℃,100rpm;
(3) HSA and Hb are mixed according to the mass ratio of 3:1, uniformly mixing, and transferring 200 mu L of the manganese porphyrin solution in the step (1) to the bottom of the mixed solution;
(4) placing the above mixture in ice water bath, performing ultrasonic treatment with cell pulverizer for 5min to obtain suspension, and treating with Na 2 CO 3 And regulating the pH value of the solution to 8, and then placing the solution in an ultrasonic cleaner for ultrasonic until the suspension becomes clear, thus obtaining the targeted oxygen-carrying nano sound sensitizer.
The zeta potential of the targeted oxygen-carrying nano sound sensitizer is larger than-30 mV, the particle size range is 100-200nm, and the results of potential and particle size can prove that the targeted oxygen-carrying nano sound sensitizer is successfully prepared. The particle size range of the targeted oxygen-carrying nano-sonosensitizer is slightly reduced compared with that of the example 2, but the particle size range is still large, and the particle size uniformity degree is not high, which is related to the ratio of the human serum albumin and the oxygen-carrying hemoglobin, the pH value of the solution and the ultrasonic time. The targeted oxygen-carrying nano sound sensitizer with more uniform particle size can be prepared by continuously optimizing the conditions.
Example 4 preparation method of Targeted oxygen-carrying nanosonic agent
In this example, the ratio of human serum albumin to oxygen-carrying hemoglobin, the pH value of the system, and the time of ultrasound are different from those of example 1, the pH value directly affects the particle size of the oxygen-carrying nanoacoustic sensitizer, and the particle size directly determines the enrichment amount of the oxygen-carrying nanoacoustic sensitizer at the tumor site. The ultrasonic time directly affects the particle size of the oxygen-carrying nano-sonosensitizer, and the ratio of human serum albumin to oxygen-carrying hemoglobin can also affect the particle size.
The method specifically comprises the following steps:
(1) Preparation of manganese porphyrin
(1) Mixing 5,10,15, 20-tetra (4-carboxyphenyl) porphyrin (PP) and manganese sulfate in an equal molar ratio into anhydrous DMF solution, stirring under the protection of argon, heating and refluxing for 4 hours, monitoring the reaction progress by a UV-Vis absorption spectrometer, stopping the reaction after the reaction liquid is changed from black red to grass green and the Q band peak is changed from 4 to 2 with a certain degree of red shift, and cooling to room temperature;
(2) the precipitate was filtered, washed with deionized water and dried in vacuo. Separating by column chromatography, and taking silica gel as stationary phase, wherein the volume ratio is 3:1 as mobile phase. And (5) rotary evaporation at low temperature, drying and collecting a sample to obtain manganese porphyrin (MnPP).
(2) Preparation of targeted oxygen-carrying nano sound sensitizer
(1) Weighing 3mg of manganese porphyrin, and dissolving in 300 mu L of chloroform;
(2) 7.5mg of Hb powder was weighed, dissolved in 3mL of ultrapure water, and placed in a shaker for reaction for 1.5h under the following conditions: 37 ℃,150rpm;
(3) HSA and Hb are mixed according to the mass ratio of 3:1, uniformly mixing, and transferring 300 mu L of manganese porphyrin solution in the step (1) to the bottom of the mixed solution;
(4) placing the above mixture in ice water bath, performing ultrasonic treatment with cell pulverizer for 12.5min to obtain suspension, and treating with Na 2 CO 3 And regulating the pH value of the solution to 7.5, and then placing the solution in an ultrasonic cleaner for ultrasonic until the suspension becomes clear, thus obtaining the targeted oxygen-carrying nano sound sensitizer.
The zeta potential of the targeted oxygen-carrying nano sound sensitizer is larger than-30 mV, the particle size range is 100-150nm, and the results of potential and particle size can prove that the targeted oxygen-carrying nano sound sensitizer is successfully prepared. The oxygen-carrying nano sound sensitizer can be enriched to tumor sites more efficiently in vivo.
The particle size means that the amount of the supported sound sensitive agent is different, so that the oxygen carrying amount is different, but the particle size directly determines the enrichment amount of the nano sound sensitive agent at the tumor part, and in general, the targeted oxygen carrying nano sound sensitive agent is easier to enrich at the tumor part when the particle size is 100-150nm.
In examples 1-4, the particle sizes of the oxygen-carrying nano sound-sensitive agents prepared were different, and the factors influencing the particle sizes were: the ratio of human serum albumin and oxyhemoglobin, the pH value of the system and the ultrasonic time. According to the invention, various preparation conditions are searched, and FIG. 1 is a UV-Vis absorption spectrum diagram of the manganese porphyrin sound-sensitive molecule in the embodiment, and the Q band peaks of the prepared manganese porphyrin are converted from 4 to 2 with a certain degree of red shift (see a dotted line frame of FIG. 1), so that the manganese porphyrin sound-sensitive molecule can be effectively prepared by the preparation method. Fig. 2 is a transmission electron microscope image of the targeted oxygen-carrying nano-acoustic sensitizer in the embodiment, and the shape rule of the prepared targeted oxygen-carrying nano-acoustic sensitizer and the particle size of 100-150nm can be seen, which illustrates that the preparation method of the invention can effectively prepare the targeted oxygen-carrying nano-acoustic sensitizer.
The targeting oxygen-carrying nano sound sensitizer particles prepared by the embodiment are most uniform, have the highest oxygen carrying capacity and can be better targeted and accumulated to tumor sites. The preparation conditions and proportions of this example are most preferred. The results of animal experiments can also be described, see in particular example 5 and example 6.
Example 5 the targeting oxygen-carrying nanosonosensitizer of the present invention effectively carries oxygen molecules into tumors
The targeted oxygen-carrying nano-acoustic sensitizer prepared in example 4 is injected into a tumor-bearing mouse (directly available) through tail vein, and is measured by a small animal photoacoustic instrument before injection and after injection for 3 hours, the result is shown in fig. 3, the control group is a control group only added with phosphate buffer solution, and the result shows that compared with the control group, the targeted oxygen-carrying nano-acoustic sensitizer has obvious photoacoustic signals (as indicated by white arrows), so that the targeted oxygen-carrying nano-acoustic sensitizer can effectively improve the tumor hypoxia microenvironment.
Example 6 the oxygen-carrying nanosonosensitizer of the present invention was effective in inhibiting tumor growth
The targeted oxygen-carrying nano-sized sound-sensitive agent prepared in the embodiment 4 is injected into a tumor-bearing mouse (directly available) by tail vein, after 3 hours, ultrasonic treatment is started for 5 minutes, the mouse is killed, the tumor is taken out to measure the tumor volume, the result is shown in fig. 4, PBS is a control group only added with phosphate buffer solution, US represents ultrasonic, and the result shows that the tumor volume of the targeted oxygen-carrying nano-sized sound-sensitive agent is obviously reduced compared with that of the control group under the action of ultrasonic, so that the targeted oxygen-carrying nano-sized sound-sensitive agent can effectively inhibit the tumor growth.
In conclusion, the targeting oxygen-carrying nano sound sensitizer is prepared by adopting a one-step ultrasonic method to hybridize Human Serum Albumin (HSA) and oxygen-carrying hemoglobin (Hb) and wrapping hydrophobic sound sensitizer manganese porphyrin (MnPP). The preparation process is simple, and the prepared targeting oxygen-carrying nano sound sensitizer has stable property, high bioavailability and good targeting property, can efficiently and targetedly deliver exogenous oxygen molecules and MnPP into the tumor, improves the anoxic microenvironment of the tumor and improves the sound power curative effect.
1. The preparation method can prepare a large volume of targeted oxygen-carrying nano sound sensitizer, can prepare more than a few liters, and the volume of the nano particles obtained by the preparation method in the prior art is hundreds of milliliters at most, so the preparation method provides a foundation for the amplified production and clinical research of the nano particles.
2. The targeted oxygen-carrying nano sound sensitizer prepared by the invention can be stably stored, and does not have sedimentation or flocculation phenomenon in one year.
3. The preparation method is simple and easy to implement, and the targeted oxygen-carrying nano sound-sensitive agent with uniform particle size can be prepared by adding the raw materials in two steps under stirring, does not need any high-temperature and complex equipment or harsh reaction conditions, and is convenient to operate and popularize.
4. After complexing the metal manganese ion and the macrocyclic compound with the porphyrin structure, the phototoxicity of the porphyrin sound-sensitive agent is reduced, and the safety is improved.
5. The invention improves the water solubility of the manganese porphyrin sound-sensitive agent, thereby improving the bioavailability thereof.
6. The human serum albumin has a tumor specific targeting function, so that the oxygen-carrying nano sound sensitizer has good targeting property.
The foregoing description of the preferred embodiments of the invention is not intended to limit the invention to the precise form disclosed, and any such modifications, equivalents, and alternatives falling within the spirit and scope of the invention are intended to be included within the scope of the invention.
Claims (5)
1. The preparation method of the targeted oxygen-carrying nano sound sensitizer is characterized by comprising the following steps of:
(1) Preparation of manganese porphyrin: mixing 5,10,15, 20-tetra (4-carboxyphenyl) porphyrin and metal manganese salt, filtering to precipitate, drying and separating; the 5,10,15, 20-tetra (4-carboxyphenyl) porphyrin and the manganese metal salt are in an equimolar ratio; the metal manganese salt comprises at least one of manganese chloride, manganese sulfate or manganese acetate;
(2) Preparing a targeted oxygen-carrying nano sound sensitizer by using human serum albumin, oxygen-carrying hemoglobin and manganese porphyrin obtained in the step (1);
weighing 3mg of manganese porphyrin, and weighing 7.5mg of oxyhemoglobin-loaded powder, wherein the mass ratio of human serum albumin to the oxyhemoglobin-loaded powder is 3:1, a step of; the step (2) comprises the step of performing ultrasonic treatment on the mixed solution of the human serum albumin, the oxygen-carrying hemoglobin and the manganese porphyrin by using a cytobreaker; the ultrasonic time is 12.5 min; the pH value of the mixed solution is 7.5;
the particle size range of the targeted oxygen-carrying nano sound-sensitive agent obtained by the steps (1) and (2) is 100-150nm.
2. The method according to claim 1, wherein the step (1) comprises a step of performing reaction protection using an inert gas.
3. The method according to claim 1, wherein the separation step in the step (1) uses column chromatography.
4. A targeted oxygen-carrying nano-sonosensitizer, characterized in that it is prepared by the preparation method of any one of claims 1-3; the targeted oxygen-carrying nano sound sensitizer is externally provided with a heterozygous protein body, and the interior of the targeted oxygen-carrying nano sound sensitizer is wrapped with manganese porphyrin; the hybrid protein body consists of human serum albumin and oxyhemoglobin; the manganese porphyrin is formed by complexing metal manganese ions with 5,10,15, 20-tetra (4-carboxyphenyl) porphyrin.
5. The use of the targeted oxygen-carrying nano sound-sensitive agent in the preparation of antitumor drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011157001.9A CN112263679B (en) | 2020-10-26 | 2020-10-26 | Targeted oxygen-carrying nano sound-sensitive agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011157001.9A CN112263679B (en) | 2020-10-26 | 2020-10-26 | Targeted oxygen-carrying nano sound-sensitive agent and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112263679A CN112263679A (en) | 2021-01-26 |
| CN112263679B true CN112263679B (en) | 2023-11-21 |
Family
ID=74342175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011157001.9A Active CN112263679B (en) | 2020-10-26 | 2020-10-26 | Targeted oxygen-carrying nano sound-sensitive agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112263679B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112546220A (en) * | 2020-12-09 | 2021-03-26 | 广东医科大学 | Preparation method and application of oxygen-carrying hybrid protein-loaded metal complex nano system |
| CN113577270A (en) * | 2021-07-09 | 2021-11-02 | 大连理工大学 | Gas-synergistic sonodynamic modified albumin drug nanoparticle, and preparation method and application thereof |
| CN114246947B (en) * | 2021-12-27 | 2023-05-23 | 中国科学院苏州纳米技术与纳米仿生研究所 | Inorganic sound sensitizer independent of oxygen in tumor microenvironment, preparation method and application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008198A (en) * | 1995-04-28 | 1999-12-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Porphyrin metal complex-albumin inclusion compound and oxygen carrier composition comprising the same |
| JP2001131200A (en) * | 1999-11-09 | 2001-05-15 | Hidetoshi Tsuchida | Porphyrin-metal complex-albumin polymer clathrate compound, and oxygen transfusion containing the same as active ingredient |
| CN107952072A (en) * | 2017-11-28 | 2018-04-24 | 深圳先进技术研究院 | Carry the preparation method of medicine oxygen carrier hybrid protein nanoparticle, carry medicine oxygen carrier hybrid protein nanoparticle and application |
| CN108030921A (en) * | 2017-12-20 | 2018-05-15 | 深圳先进技术研究院 | A kind of preparation method and applications of albumin carried metal metalloporphyrin complex nano particle |
| CN109125723A (en) * | 2017-06-15 | 2019-01-04 | 中国科学院深圳先进技术研究院 | Compound sound sensitiser, preparation method, application, application method, purposes and pharmaceutical composition |
-
2020
- 2020-10-26 CN CN202011157001.9A patent/CN112263679B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008198A (en) * | 1995-04-28 | 1999-12-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Porphyrin metal complex-albumin inclusion compound and oxygen carrier composition comprising the same |
| JP2001131200A (en) * | 1999-11-09 | 2001-05-15 | Hidetoshi Tsuchida | Porphyrin-metal complex-albumin polymer clathrate compound, and oxygen transfusion containing the same as active ingredient |
| CN109125723A (en) * | 2017-06-15 | 2019-01-04 | 中国科学院深圳先进技术研究院 | Compound sound sensitiser, preparation method, application, application method, purposes and pharmaceutical composition |
| CN107952072A (en) * | 2017-11-28 | 2018-04-24 | 深圳先进技术研究院 | Carry the preparation method of medicine oxygen carrier hybrid protein nanoparticle, carry medicine oxygen carrier hybrid protein nanoparticle and application |
| CN108030921A (en) * | 2017-12-20 | 2018-05-15 | 深圳先进技术研究院 | A kind of preparation method and applications of albumin carried metal metalloporphyrin complex nano particle |
Non-Patent Citations (2)
| Title |
|---|
| 人工氧载体研究进展;殷晓春等;《化学进展》;20110524(第05期);全文 * |
| 卟啉类化合物与人血清白蛋白相互作用的研究进展;王树军等;《化学通报》;20130618(第06期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112263679A (en) | 2021-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112263679B (en) | Targeted oxygen-carrying nano sound-sensitive agent and preparation method thereof | |
| Yang et al. | An oxygen self-sufficient NIR-responsive nanosystem for enhanced PDT and chemotherapy against hypoxic tumors | |
| US10286004B2 (en) | Targeting-enhanced anticancer nanoparticles and preparation methods of same | |
| Yang et al. | Light-activatable dual-source ROS-responsive prodrug nanoplatform for synergistic chemo-photodynamic therapy | |
| Yang et al. | Recent advances in nanosized metal organic frameworks for drug delivery and tumor therapy | |
| Zhou et al. | Designing Hypoxia‐Responsive Nanotheranostic Agents for Tumor Imaging and Therapy | |
| CN113599518B (en) | Composite sound-sensitive agent and preparation method thereof | |
| CN110215438B (en) | Preparation method and application of mesoporous silicon nanoparticles carrying anthracyclines and photosensitizers | |
| CN108210506B (en) | pH response and polypeptide targeting nano-drug delivery carrier and preparation and application thereof | |
| CN114470231B (en) | Nanometer drug-carrying system for folic acid-hydroxyalkyl starch macromolecule stable co-carrying photosensitizer and small molecule prodrug, preparation and application thereof | |
| CN104984341B (en) | A kind of preparation method of the composite Nano preparation of near-infrared laser triggering | |
| CN114344482B (en) | Multifunctional nanoparticle based on metal-organic framework and preparation method and application thereof | |
| Ma et al. | A DNA-engineered metal–organic-framework nanocarrier as a general platform for activatable photodynamic cancer cell ablation | |
| Yan et al. | Multifunctional and multimodality theranostic nanomedicine for enhanced phototherapy | |
| CN114224823A (en) | Brain glioma drug delivery system integrating chemotherapy, photodynamic therapy and chemodynamic therapy and preparation method thereof | |
| CN113648401A (en) | Hybrid nano assembly for protease inhibition sensitization photodynamic therapy and preparation and application thereof | |
| CN110917349B (en) | Bowl-shaped ISP (internet service provider) composite functional nano particle as well as preparation method and application thereof | |
| Kang et al. | Applications of nanocomposites based on zeolitic imidazolate framework-8 in photodynamic and synergistic anti-tumor therapy | |
| CN111821469A (en) | Homing targeting RSGRVSN peptide modified polyethylene glycol-polydopamine-Prussian blue composite nanoparticle and preparation method thereof | |
| CN111686250A (en) | Mitochondrion targeted photothermal therapeutic agent and preparation and application thereof | |
| CN114870011B (en) | Microneedle patch for enhancing accumulation of protoporphyrin IX in solid tumor and preparation method thereof | |
| Zhu et al. | A biocompatible pure organic porous nanocage for enhanced photodynamic therapy | |
| CN113769087B (en) | Bionic pre-quenching dual-photosensitizer co-assembled nanoparticle and preparation and application thereof | |
| CN113616806B (en) | Platinum-icodextrin-polycaprolactone macromolecular compound, nano drug-loading system and application thereof | |
| Wang et al. | Progress of porphyrin-based nanoassemblies for cancer theranostics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |